©2018 by inRegen | inRegen and the inRegen logo are trademarks of inRegen | Privacy Policy and Disclaimer

ABOUT US

​In over 50 years there was little development in the treatment of chronic kidney disease. At inRegen we are pioneers in the field of diabetic kidney treatment.

We believe there is a better way. 

Our passion about curing chronic kidney disease led us to develop a revolutionary cell therapy that harnesses the body’s intrinsic ability to repair and restore damaged kidney tissues to native-like organs and tissues. inRegen's technology has the potential to delay or

eliminate the need for dialysis and organ transplantation.

inRegen’s candidates are designed to become the

standard of care for chronic kidney disease.

HIGHLIGHTS

FDA awarded Fast Track Designation

Presentation at the Alliance for Regenerative Medicine (ARM) Investor Day 2017

ReACT Potential health care cost off-set equals approximately $250K/patient/year

Long-term durability of approximately 4 years

Improves multiple renal endocrine and filtration functions

Partnership with the National Kidney Foundation (NKF) and the American Association of Kidney Patients (AAKP)

inRegen Corporate Overview.jpg.png

WANT TO FIND OUT MORE?
CLICK BELOW TO REQUEST OUR CORPORATE PRESENTATION.